Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBB1
- Development stage
- Phase 2
- Lead developer
- Changchun BCHT Biotechnology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous (based On Typical Administration For Monoclonal Antibodies; Specific Route Not Explicitly Stated But Inferred From Clinical Context)
01
Overview
CBB1 is a natural, fully human monoclonal antibody developed as an immunotherapeutic agent for the prevention and treatment of rabies. It is designed to neutralize the rabies virus by binding to viral antigens, thereby preventing infection or progression of disease following exposure. The drug is being evaluated both as a standalone therapy and in combination with rabies vaccine or human rabies immunoglobulin (HRIG) in healthy adults. Its mechanism involves direct viral neutralization through specific antigen binding[1][6].
- Brand names
- rabies monomab CBB-1
- Other names
- Natural fully human anti-rabies monoclonal antibody CBB1Rabies mAb CBB 1
02
Targets
RABV-G (Rabies virus glycoprotein)
Beyond the preview
Go deeper on CBB1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBB1.